Summary (LLM read my papers; human bias-correction applied)

In my AI4Science / biomedical data work, I develop statistical methods that make large, heterogeneous datasets—such as genetics/proteomics and multi-center EHRs—more actionable for science: the goal is to draw conclusions that remain reliable when real-world complications arise (e.g., imperfect instruments in genetics, strong cross-hospital heterogeneity, and privacy constraints that limit data sharing).
Concretely, one line of work proposes MR-SPI, a robust Mendelian randomization approach that automatically selects valid genetic instruments and then performs post-selection inference, so causal biomarker discovery is less sensitive to invalid SNPs; it is applied to UK Biobank proteomics (912 proteins) to identify proteins associated with Alzheimer’s disease, with follow-up structural analysis via AlphaFold2. Another line of work develops SurvMaximin, a robust federated/transfer learning method for survival risk prediction that borrows strength across centers using one-time summary sharing (no patient-level data) and is designed to remain stable even when site-specific models are highly heterogeneous, improving performance especially for smaller target sites.